• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

程序性死亡-1抑制剂单药治疗后侵犯上唇红缘的皮肤鳞状细胞癌假性进展

Pseudoprogression of cutaneous squamous cell carcinoma invading the super vermillion border following programmed death-1 inhibitor monotherapy.

作者信息

Thakker Sach, Yousefzadeh Naghmeh, Al-Mondhiry Jafar

机构信息

Georgetown University School of Medicine Washington District of Columbia USA.

Sonic Healthcare Dermatopathology Sterling Virginia USA.

出版信息

Skin Health Dis. 2024 May 30;4(4):e400. doi: 10.1002/ski2.400. eCollection 2024 Aug.

DOI:10.1002/ski2.400
PMID:39104642
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11297434/
Abstract

A 55-year-old woman with a moderately differentiated cutaneous squamous cell carcinoma (cSCC) of the upper lip experienced initial tumour growth and new lymphadenopathy after starting immunotherapy with Cemiplimab, but achieved complete remission with no adverse events after five infusions. This case underscores the potential of immunotherapy for cSCC in sensitive head and neck areas and illustrates the phenomenon of pseudoprogression, where apparent tumour growth can occur before clinical improvement.

摘要

一名55岁女性，患有上唇中度分化的皮肤鳞状细胞癌（cSCC），在开始使用西米普利单抗进行免疫治疗后，肿瘤最初出现生长，并伴有新的淋巴结病，但在五次输注后实现了完全缓解，且无不良事件。该病例强调了免疫疗法在敏感头颈部区域治疗cSCC的潜力，并说明了假进展现象，即在临床改善之前可能会出现明显的肿瘤生长。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c96/11297434/c1924f7626b0/SKI2-4-e400-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c96/11297434/5fea212c56bd/SKI2-4-e400-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c96/11297434/c1924f7626b0/SKI2-4-e400-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c96/11297434/5fea212c56bd/SKI2-4-e400-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c96/11297434/c1924f7626b0/SKI2-4-e400-g001.jpg

相似文献

1
Pseudoprogression of cutaneous squamous cell carcinoma invading the super vermillion border following programmed death-1 inhibitor monotherapy.程序性死亡-1抑制剂单药治疗后侵犯上唇红缘的皮肤鳞状细胞癌假性进展
Skin Health Dis. 2024 May 30;4(4):e400. doi: 10.1002/ski2.400. eCollection 2024 Aug.
2
Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.晚期皮肤鳞状细胞癌对免疫疗法的反应：病例报告
Stem Cell Investig. 2021 Sep 6;8:19. doi: 10.21037/sci-2020-071. eCollection 2021.
3
Successful Treatment of Cutaneous Squamous Cell Cancer with Cemiplimab-A Report of Two Cases Demonstrating the Management of Pseudoprogression and Adverse Events.西米普利单抗成功治疗皮肤鳞状细胞癌——两例病例报告，展示假性进展和不良事件的处理
J Clin Med. 2024 Jul 19;13(14):4236. doi: 10.3390/jcm13144236.
4
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.西妥昔单抗在局部晚期和转移性皮肤鳞状细胞癌中的真实世界数据。
Eur J Cancer. 2021 Nov;157:250-258. doi: 10.1016/j.ejca.2021.08.018. Epub 2021 Sep 15.
5
Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.病例系列：西米普利单抗和纳武单抗免疫疗法有望用于治疗晚期或转移性皮肤鳞状细胞癌。
Case Rep Oncol. 2023 Oct 16;16(1):1156-1165. doi: 10.1159/000533759. eCollection 2023 Jan-Dec.
6
Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab.在转移性皮肤鳞状细胞癌对西米普利单抗程序性细胞死亡蛋白1阻断完全缓解期间，同时发生高分期皮肤鳞状细胞癌。
JAAD Case Rep. 2021 Oct 20;18:23-25. doi: 10.1016/j.jdcr.2021.10.009. eCollection 2021 Dec.
7
Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma.病例报告：接受西米普利单抗治疗的多灶性局部晚期皮肤鳞状细胞癌患者并发自身免疫性寻常型天疱疮
Front Oncol. 2021 Aug 23;11:691980. doi: 10.3389/fonc.2021.691980. eCollection 2021.
8
Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma.免疫疗法可避免皮肤鳞状细胞癌患者行眼眶内容物剜除术
Front Oncol. 2022 Jan 18;11:796197. doi: 10.3389/fonc.2021.796197. eCollection 2021.
9
Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.西妥昔单抗治疗局部晚期皮肤鳞状细胞癌 3 例独特病例系列
J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221121408. doi: 10.1177/23247096221121408.
10
Global status of research on cutaneous squamous cell carcinoma and its programmed cell death: Bibliometric and visual analysis from 2012 to middle 2022.皮肤鳞状细胞癌及其程序性细胞死亡的全球研究现状：2012年至2022年年中的文献计量学与可视化分析
Front Oncol. 2023 Apr 11;13:1099382. doi: 10.3389/fonc.2023.1099382. eCollection 2023.

本文引用的文献

1
Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma.高危和晚期皮肤鳞状细胞癌患者不断发展的治疗的循证共识建议
JID Innov. 2021 Aug 25;1(4):100045. doi: 10.1016/j.xjidi.2021.100045. eCollection 2021 Dec.
2
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.CheckMate 141 随机 3 期临床试验的亚组分析：纳武利尤单抗治疗复发或转移性头颈部鳞状细胞癌，超出 RECIST 定义的进展
Cancer. 2019 Sep 15;125(18):3208-3218. doi: 10.1002/cncr.32190. Epub 2019 Jun 27.
3
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
西妥昔单抗联合 PD-1 抑制剂治疗晚期皮肤鳞状细胞癌的疗效和安全性
N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.